| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 01/06/2004 | US6673580 Genetically engineering thrombopoietin for use in the treatment of thrombocytopenia; obtain polypeptide, adjust epitopes, recover polypeptide, administer to patients |
| 01/06/2004 | US6673382 Containing sugar to provide freezing and thawing stability; foods, drinks; treatment of anemia |
| 01/06/2004 | US6673379 Use of non-alkalized cocoa solids in a drink |
| 01/06/2004 | US6673365 Administering hooc-ch2-(r)-cgl-aze-pab where cgl is cyclohexylglycine, aze is azetidine-2-carboxylic acid, and pab is 1-amidino-4-aminomethylbenzene |
| 01/06/2004 | CA2135083C Antibodies to p-selectin and their uses |
| 01/06/2004 | CA2119762C Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof |
| 01/06/2004 | CA2096109C Tissue factor based prothrombin time reagent |
| 01/02/2004 | EP1375662A1 A novel polypeptide compose substance for promoting blood and blood vessel cell growth |
| 01/02/2004 | EP1375482A1 Benzamidine derivative |
| 01/02/2004 | EP1374896A1 Blood rheology improving agents |
| 01/02/2004 | EP1374890A2 Thrombopoietin compositions for increasing circulating platelets |
| 01/02/2004 | EP1374889A1 Method of inducing angiogenesis by micro-organs |
| 01/02/2004 | EP1374865A1 Use of R,S-(+/-)-alpha-lipoic acid, R(+)-alpha-lipoic acid or S-(-)-alpha-lipoic acid in reduced or oxidised form, or their metabolites as well as their salts, esters or amides, for the treatment of hearing disorders |
| 01/02/2004 | EP1373517A2 Human kinases |
| 01/02/2004 | EP1373493A1 Coagulation factor vii derivatives |
| 01/02/2004 | EP1373489A2 Human dual specificity protein phosphatase 7-like protein |
| 01/02/2004 | EP1373475A2 Immunotherapy based on dendritic cells |
| 01/02/2004 | EP1373317A2 Nuclear hormone receptor ligand binding domains |
| 01/02/2004 | EP1373316A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373315A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373313A2 Proteins and nucleic acids encoding same |
| 01/02/2004 | EP1373306A2 Cytoskeletion-associated proteins |
| 01/02/2004 | EP1373304A1 INTEGRIN ALPHA IIbBETA 3 ACTIVIVING PEPTIDES AND THEIR USE |
| 01/02/2004 | EP1373269A1 Jun kinase inhibitors |
| 01/02/2004 | EP1373262A2 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors |
| 01/02/2004 | EP1373259A1 Pyridazinone aldose reductase inhibitors |
| 01/02/2004 | EP1373257A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/02/2004 | EP1373242A1 Dimeric isoflavones |
| 01/02/2004 | EP1373239A1 Benzofuran derivatives |
| 01/02/2004 | EP1373233A1 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 01/02/2004 | EP1373204A2 Heterocyclic compounds |
| 01/02/2004 | EP1373202A1 Preparation of non-crystalline atorvastatin calcium |
| 01/02/2004 | EP1373194A1 BENZAMIDE INHIBITORS OF FACTOR Xa |
| 01/02/2004 | EP1373191A1 Acylated indanyl amines and their use as pharmaceuticals |
| 01/02/2004 | EP1372737A2 Preparation for the prophylaxis of restenosis |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372724A2 Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| 01/02/2004 | EP1372716A2 Blood cell production via activation of the hemoglobin scavenger receptor (cd163) |
| 01/02/2004 | EP1372700A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 01/02/2004 | EP1372696A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/02/2004 | EP1372695A2 Cell damage inhibitor |
| 01/02/2004 | EP1372690A2 93870, a human g-protein coupled receptor and uses therefor |
| 01/02/2004 | EP1372688A2 Somatostatin antagonists |
| 01/02/2004 | EP1372682A2 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders |
| 01/02/2004 | EP1372664A1 Use of certain steroids for treatment of blood cell deficiencies |
| 01/02/2004 | EP1372656A1 Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors |
| 01/02/2004 | EP1372654A2 Quinoline inhibitors of hyak1 and hyak3 kinases |
| 01/02/2004 | EP1372647A2 Use of substituted imidazo 1,2-a]-pyridine compounds as medicaments |
| 01/02/2004 | EP1372635A1 Use of creatine for the amelioration of oxidative stress |
| 01/02/2004 | EP1372632A1 Proliferative activator receptor (ppar) compounds |
| 01/02/2004 | EP1372529A2 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 01/02/2004 | EP0871664B1 Mobilization of hematopoietic stem cells using a chemokine |
| 01/01/2004 | US20040003422 An expression cassette containing the proopiomelanocortin (POMC) enhancer, and a nucleic acid sequence encoding POMC contains at least one exon, wherein a polylinker having an unique site for restriction enzyme is inserted into the exon; gene regulates weight and fat mass |
| 01/01/2004 | US20040002613 Synthesis of benzonitriles from substituted benzoic acid |
| 01/01/2004 | US20040002539 Enzyme inhibitors; anticoagulants; blood collecting device |
| 01/01/2004 | US20040002535 Methods of treating hormone-related conditions using thio-oxindole derivatives |
| 01/01/2004 | US20040002524 Cardiovascular disorders; osteoporosis; central nervous system disorders |
| 01/01/2004 | US20040002508 Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders |
| 01/01/2004 | US20040002507 Rho-kinase inhibitors |
| 01/01/2004 | US20040002496 Compositions useful as inhibitors of protein kinases |
| 01/01/2004 | US20040002494 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 01/01/2004 | US20040002481 Novel 4-dedimethylaminotetracycline derivatives |
| 01/01/2004 | US20040002446 Central nervous system disorders; brain disorders; administering genetic engineered thrombomodulin |
| 01/01/2004 | US20040002134 Novel nucleic acid sequences encoding human KIAA0768 protein-like and human protein PRO228-like polypeptides |
| 01/01/2004 | US20040002113 Detection and treatment methods for type I diabetes |
| 01/01/2004 | US20040002066 36 human secreted proteins |
| 01/01/2004 | US20040001824 Cell proliferation inhibitors |
| 12/31/2003 | WO2004001424A1 Materials and methods for inductions of immune tolerance |
| 12/31/2003 | WO2004000854A1 Sulfur-containing phospholipid derivatives |
| 12/31/2003 | WO2004000846A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 12/31/2003 | WO2004000842A1 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors |
| 12/31/2003 | WO2004000839A1 Thiazole derivatives as phosphodiesterase iv inhibitors |
| 12/31/2003 | WO2004000818A1 Crystalline (r)-2-(4-amidinophenylaminomethyl)-1-methyl-5-(1-(carboxymethylamino)-1(pyrrolidinocarbonyl)-ethyl)-benzimidazole, and the use thereof as antithrombotic agents |
| 12/31/2003 | WO2004000817A2 Benzimidazole compounds and their use as estrogen agonists/antagonists |
| 12/31/2003 | WO2004000816A1 Androgen receptor agonist |
| 12/31/2003 | WO2004000808A2 N-substituted piperidine derivatives as serotonin receptor agents |
| 12/31/2003 | WO2004000801A2 Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions |
| 12/31/2003 | WO2004000368A1 Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
| 12/31/2003 | WO2004000366A1 Pegylated factor vii glycoforms |
| 12/31/2003 | WO2004000348A1 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases |
| 12/31/2003 | WO2004000347A1 Stabilised solid compositions of factor vii polypeptides |
| 12/31/2003 | WO2004000333A1 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives |
| 12/31/2003 | WO2004000245A1 Promoter for uptake of basic amino acid into cell and cosmetic or drug composition |
| 12/31/2003 | WO2004000225A2 Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| 12/31/2003 | WO2004000219A2 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
| 12/31/2003 | WO2003077832A3 Dexanabinol and dexanabinol analogs regulate inflammation related genes |
| 12/31/2003 | WO2003074513A3 Indole amide derivatives and their use as glycogen phosphorylase inhibitors |
| 12/31/2003 | WO2003060077A3 Endothelial stem cells, populations, methods of isolation and use thereof |
| 12/31/2003 | WO2003059288A3 Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds |
| 12/31/2003 | WO2003059269A3 Acridone inhibitors of impdh enzyme |
| 12/31/2003 | WO2003055912A3 Secreted proteins |
| 12/31/2003 | WO2003013499A3 Drugs for vasculopaties |
| 12/31/2003 | WO2002070562A3 Nuclear hormone receptor ligand binding domain |
| 12/31/2003 | WO2002060378A3 Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 12/31/2003 | WO2002055075A3 Compounds and methods for regulating cell differentiation |
| 12/31/2003 | WO2002047708A3 Selective cox-2 inhibition from edible plant extracts |
| 12/31/2003 | WO2002040671A3 Immunoglobulin superfamily proteins |
| 12/31/2003 | CN1464791A Compositions for protein delivery via the pulmonary route |
| 12/31/2003 | CN1464057A Chemokine-like factor superfamily having skeletal muscle stimulating activity and immunoregulation function |
| 12/31/2003 | CN1463977A Process for extracting amygdalin and use thereof |